 |
|
|
| |
GSK2248761, an NNRTI with Activity Against Common NNRTI Resistance Mutants, Did Not Select for NNRTI Resistance Mutations in Two 7-Day Monotherapy Studies
|
| |
| |
Reported by Jules Levin
ICAAC Sept 14 2010 Boston
The 30mg dose appears suboptimal & the other diseases appear to provide similar declines in viral load. Dr St Clair said 100 & 200mg were selected to be studied.
|
| |
|
|
|
|
|
